Skip to main content
Equibles
CRVS logo

CRVS · Corvus Pharmaceuticals, Inc.

Track CRVS — free

Use CRVS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CRVS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.67 +0.34 (+2.34%)
Market Cap
$1.21B
Shares
84.12M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.33 Open$15.15 Day$14.14–15.31 52W close$5.19–25.52 Avg vol 30d878K Short int18.3M · 21.8% float · 22.5d Short vol66% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Oct 15, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +7%
      above
      Price vs 50-day avg +3%
      above
      RSI (14) 50
      neutral
      MACD trend Positive
      52-week position 45%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return +5%
      trailing
      6-month return −22%
      trailing
      YTD return +86%
      this year
      Relative strength −33%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $14 › 200d $13 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +40 funds added
      Insider flow Accumulating
      Net +$250.2K over 90 days · 0% sells
      Short interest Rising
      21.77% of float · ▲ +1.4% MoM · 22.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      173 holders — near 3-yr high, broad support
      Squeeze score 80
      high risk · 0–100
      Fundamentals
      Strong
      EPS growth +48%
      Y/Y
      Free cash flow $-33.0M
      Balance sheet $4.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 179%
      annualized · 1-yr
      Max drawdown −56%
      past year
      ATR 5.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Prior guidance period ended · from the Earnings Call filed Sep 30, 2023
      Net cash used in operating activities · full year 2023 $22M – $23M
      Projected cash balance · as of December 31, 2023 $27M – $28M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +7% Bullish
      Price vs 50-day avg
      +3% Bullish
      RSI (14)
      50 Neutral
      MACD trend
      Positive Bullish
      52-week position
      45% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $14 › 200d $13 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +40 funds added
      Insider flow Accumulating
      Net +$250.2K over 90 days · 0% sells
      Short interest Rising
      21.77% of float · ▲ +1.4% MoM · 22.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      173 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $5 Now $14 · 45% Range high $26
      vs 200-day avg +7% vs 50-day avg +3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CRVS
      Corvus Pharmaceuticals, Inc.
      this stock
      		$1.21B +86.1% — — 21.8%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      173
      % held
      86.5%
      Net QoQ
      +1.1M sh
      Top holder
      ORBIMED ADVISORS LLC
      Held Float
      View
      Held by Funds
      Fund positions
      171
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      18.3M
      Days to cover
      22.5d
      Change
      +248.3K sh
      View
      Short Volume
      Short vol %
      66%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      10.0K
      Value
      $132.6K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      35.4%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$250.2K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-15.3M
      EPS diluted
      $-0.53
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      17
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View
      Investor Relations
      Latest news
      Corvus Pharmaceuticals Provides B…
      Published
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CRVS -5.4% +4.8% -21.5% +8.1% +86.1%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY -3.4% +1.4% -32.7% +6.0% +74.3%
      Key facts CIK 1626971 CUSIP 221015100 13F (30d) 165 filings 163 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)